MEDA Pharma GmbH & Co. KG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1919-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.medapharma.de
Clinical Trials
36
Active:11
Completed:21
Trial Phases
4 Phases
Phase 1:7
Phase 2:4
Phase 3:9
+1 more phases
Drug Approvals
1
NMPA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Phase 3
9 (32.1%)Phase 4
8 (28.6%)Phase 1
7 (25.0%)Phase 2
4 (14.3%)Azelastine Allergen Chamber - Onset of Action Study
Phase 2
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 84
- Registration Number
- NCT06126952
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
Real-world Evidence Study on Cystistat
Active, not recruiting
- Conditions
- Interstitial Cystitis and Bladder Pain Syndrome
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 74
- Registration Number
- NCT05544695
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Dymista Allergen Chamber - Onset of Action Study
Phase 4
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 216
- Registration Number
- NCT04652245
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
DYmista NAsal Spray in CHInese Patients
Phase 3
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 900
- Registration Number
- NCT03599791
- Locations
- 🇨🇳
Investigational Site 2, Tianjin, Tianjin, China
🇨🇳Investigational Site 3, Tianjin, Tianjin, China
🇨🇳Investigational Site 4, Tianjin, Tianjin, China
MP-AzeFlu Allergen Chamber - Onset of Action Study
Phase 4
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 82
- Registration Number
- NCT03004131
- Locations
- 🇨🇦
Inflamax Research, Mississauga, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found